Amaryl Related Published Studies
Well-designed clinical trials related to Amaryl (Glimepiride)
Pioglitazone vs glimepiride: Differential effects on vascular endothelial function in patients with type 2 diabetes. [2009.07]
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. [2009.02.07]
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes mellitus (LEAD-2 Met). [2008.10.17]
Improvement of glycaemic and lipid profiles with muraglitazar plus metformin in patients with type 2 diabetes: an active-control trial with glimepiride. [2008.09]
Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. [2008.04.02]
Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. [2007.11]
Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. [2006.12.06]
Bioequivalence assessment of the two brands of glimepiride tablets. [2006.12]
Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. [2006.10]
Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial. [2006.05]
Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. [2006.05]
Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial. [2006.04]
Once-daily insulin glargine administration in the morning compared to bedtime in combination with morning glimepiride in patients with type 2 diabetes: an assessment of treatment flexibility. [2006.03]
Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial. [2006.03]
Efficacy of glimepiride on insulin resistance, adipocytokines, and atherosclerosis. [2006.02]
Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride. [2006.01]
Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride. [2005.11]
Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes. [2005.08]
A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. [2005.07]
Repaglinide has more beneficial effect on cardiovascular risk factors than glimepiride: data from meal-test study. [2005.06]
Efficacy of glimepiride in Japanese type 2 diabetic subjects. [2005.06]
Long-term effect of glimepiride and rosiglitazone on non-conventional cardiovascular risk factors in metformin-treated patients affected by metabolic syndrome: a randomized, double-blind clinical trial. [2005.05]
Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. [2005.05]
Bioequivalence evaluation of two brands of glimepiride 4 mg tablets in healthy subjects. [2005.04]
Results of a randomized, double-blind, placebo-controlled study administering glimepiride to patients with type 2 diabetes mellitus inadequately controlled with rosiglitazone monotherapy. [2004.11]
GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. [2004.08]
Use of glimepiride and insulin sensitizers in the treatment of type 2 diabetes--a study in Indians. [2004.06]
Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: comparison between glimepiride and metformin. [2004.06]
[Efficacy and safety of glimepiride plus metformin in a single presentation, as combined therapy, in patients with type 2 diabetes mellitus and secondary failure to glibenclamide, as monotherapy] [2004.05]
Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. [2004.05]
Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial. [2004.05]
Repaglinide is more efficient than glimepiride on insulin secretion and post-prandial glucose excursions in patients with type 2 diabetes. A short term study. [2004.02]
Change in patients' body weight after 12 months of treatment with glimepiride or glibenclamide in Type 2 diabetes: a multicentre retrospective cohort study. [2003.12]
Prospective multicentre trial comparing the efficacy of, and compliance with, glimepiride or acarbose treatment in patients with type 2 diabetes not controlled with diet alone. [2003.08]
Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. [2003.06.17]
Comparison of the micro- and macro-vascular effects of glimepiride and gliclazide in metformin-treated patients with Type 2 diabetes: a double-blind, crossover study. [2003.06]
Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors. [2003.02]
Plasma adiponectin plays an important role in improving insulin resistance with glimepiride in elderly type 2 diabetic subjects. [2003.02]
Efficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. [2003.01]
Vascular effects of glibenclamide vs. glimepiride and metformin in Type 2 diabetic patients. [2002.02]
The NEPI antidiabetes study (NANSY). 1: short-term dose-effect relations of glimepiride in subjects with impaired fasting glucose. [2001.12]
Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride. [2001.11]
Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. [2001.10]
Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride. [2001.04]
Effect of rifampicin on the pharmacokinetics and pharmacodynamics of glimepiride. [2000.12]
Appropriate timing of glimepiride administration in patients with type 2 diabetes millitus: a study in Mediterranean countries. [2000.08]
Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. [1999.03]
Comparative effects of glimepiride and glibenclamide on blood glucose, C-peptide and insulin concentrations in the fasting and postprandial state in normal man. [1999]
Biopharmaceutical characterization of oral immediate release drug products. In vitro/in vivo comparison of phenoxymethylpenicillin potassium, glimepiride and levofloxacin. [1998.11]
A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful. [1998.07]
Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group. [1998.07]
Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients. [1997.07]
Short-term comparison of once- versus twice-daily administration of glimepiride in patients with non-insulin-dependent diabetes mellitus. [1997.06]
Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group. [1996.11]
The effects of acute exercise on metabolic control in type II diabetic patients treated with glimepiride or glibenclamide. [1996.09]
The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus. [1996.09]
Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group. [1996.09]
Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide. [1996.09]
A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group. [1996.08]
Pharmacokinetics and pharmacodynamics of the hydroxymetabolite of glimepiride (Amaryl) after intravenous administration. [1996]
Dose linearity assessment of glimepiride (Amaryl) tablets in healthy volunteers. [1994]
Absolute bioavailability of glimepiride (Amaryl) after oral administration. [1994]
Dose relationship of stimulated insulin production following intravenous application of glimepiride in healthy man. [1993.08]
Well-designed clinical trials possibly related to Amaryl (Glimepiride)
Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT. [2009.10.12]
CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone. [2009.09.10]
Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. [2009.08]
Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. [2009.05]
Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. [2009.04.21]
Impact of glitazones on metabolic and haemodynamic parameters in patients with type 2 diabetes mellitus. [2009.04]
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). [2009.03]
Glucose control and vascular complications in veterans with type 2 diabetes. [2009.01.08]
Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone. [2009]
Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus. [2008.04.22]
Insulin glargine added to therapy with oral antidiabetic agents improves glycemic control and reduces long-term complications in patients with type 2 diabetes - a simulation with the Diabetes Mellitus Model (DMM). [2007.12]
Insulin glargine versus NPH insulin therapy in Asian Type 2 diabetes patients. [2007.04]
Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus. [2007.02]
Relaxin expression correlates significantly with serum changes in VEGF in response to antidiabetic treatment in male patients with type 2 diabetes mellitus. [2007]
The switch from sulfonylurea to preprandial short- acting insulin analog substitution has an immediate and comprehensive beta-cell protective effect in patients with type 2 diabetes mellitus. [2006.06]
Improvement in C-reactive protein and advanced glycosylation end-products in poorly controlled diabetics is independent of glucose control. [2006.04]
Influence of glucose control and improvement of insulin resistance on microvascular blood flow and endothelial function in patients with diabetes mellitus type 2. [2005.10]
Pharmacological PPARgamma stimulation in contrast to beta cell stimulation results in an improvement in adiponectin and proinsulin intact levels and reduces intima media thickness in patients with type 2 diabetes. [2005.08]
Pioneer study: PPARgamma activation results in overall improvement of clinical and metabolic markers associated with insulin resistance independent of long-term glucose control. [2005.08]
Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. [2005.06.21]
Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. [2005.05.17]
Electronic pill-boxes in the evaluation of oral hypoglycemic agent compliance. [2005.04]
The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus. [2005.03]
Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. [2005.02]
Effect of rosiglitazone versus insulin on the pancreatic beta-cell function of subjects with type 2 diabetes. [2004.11]
Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. [2004.06]
Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial. [2003.11]
Efficacy of sulfonylureas with insulin in type 2 diabetes mellitus. [2003.11]
Lispro insulin and metformin versus other combination in the diabetes mellitus type 2 management after secondary oral antidiabetic drug failure. [2003.06]
Combined bedtime insulin--daytime sulphonylurea regimen compared with two different daily insulin regimens in type 2 diabetes: effects on HbA1c and hypoglycaemia rate--a randomised trial. [2003.03]
Pharmacokinetics, tolerability, and fructosamine-lowering effect of a novel, controlled-release formulation of alpha-lipoic acid. [2002.01]
Sulfonylurea treatment of type 2 diabetic patients does not reduce the vasodilator response to ischemia. [2001.04]
Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients. [2000.01]
Other research related to Amaryl (Glimepiride)
Effect of sulfonylureas on switching to insulin therapy (twice-daily biphasic insulin aspart 30): comparison of twice-daily biphasic insulin aspart 30 with or without glimepiride in type 2 diabetic patients poorly controlled with sub-maximal glimepiride. [2009.10]
The European Exenatide study of long-term exenatide vs. glimepiride for type 2 diabetes: rationale and patient characteristics. [2009.09.13]
Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone. [2009.02.26]
Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. [2009.02]
Glimepiride treatment upon reperfusion limits infarct size via the phosphatidylinositol 3-kinase/Akt pathway in rabbit hearts. [2009.02]
|
